Why AstraZeneca could dominate the European vaccine market

Demand in the United States may be limited, as President Joe Biden recently purchased enough doses of the vaccine from Pfizer (NYSE: PFE) and Moderna (NASDAQ: mRNA) to immunize almost all Americans. But global demand remains high. In this Motley Fool Live video registered on February 26, 2021, Corinne Cardina, Head of Health and Cannabis Bureau, and Adria Cimino, Fool.com Contributor, discuss opportunities in Europe and why AstraZeneca might have an advantage.

Corinne Cardina: Let’s talk about the demand. In the United States, we have 600 million doses that have been secured. That’s enough to vaccinate 330 million people. Is there still a demand in the United States? And what do we know about global demand and the price landscape?

Adria Cimino: OK. Well, as for the United States, I am concerned about the short term demand in the United States, I think due to this big order from the US government to cover the whole country in the short term, I think this could be something that could prevent a lot of other companies from entering the US market as early as this year, unless Pfizer or Moderna really has a production issue and they can’t deliver the full ordered. It will be different, but otherwise I don’t know

see how another company could make inroads at this point. The opportunity in the United States is more long term. It’s more the idea of ​​a company that has a good booster or can handle new strains or a single vaccine and things like that. It is something to watch out for.

As far as global demand goes, I think it’s pretty high. If you look at Europe, it is really struggling. The authorization and ordering of vaccine doses has been very slow. It’s a market where I think there could be a lot of potential. Now the only thing is that the prices have been generally lower in Europe which could be a problem.

In addition, Europe has many doses of vaccines from AstraZeneca (NASDAQ: AZN). AstraZeneca, as we said, is not profitable. So they were able to get a lower price for this vaccine than they would from another company making a profit. It might be difficult for another company trying to enter the European market at this time. This is something that we will just have to keep an eye on in the future.

This article represents the opinion of the author, who may disagree with the “official” recommendation position of a premium Motley Fool consulting service. We are heterogeneous! Challenging an investment thesis – even one of our own – helps us all to think critically about investing and make decisions that help us become smarter, happier, and richer.

Source link

About Nancy Owens

Nancy Owens

Check Also

Sensex, Nifty end almost flat; pharmaceutical stocks are climbing

Major stock indexes ended almost flat with some positive bias after a volatile trade on …

Leave a Reply

Your email address will not be published. Required fields are marked *